Patents by Inventor Pierre Corbeau

Pierre Corbeau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of HIV Infections and uses thereof
    Publication number: 20130303490
    Abstract: The invention relates to compounds which are agonists of at least one receptor selected from S1PR1, S1PR2, S1PR3, S1PR4 and S1PR5 receptors, for use in methods for treating HIV infections in humans or animals.
    Type: Application
    Filed: December 12, 2011
    Publication date: November 14, 2013
    Applicant: Centre National De La Recherche Scientifique-CNRS
    Inventors: Vincent Francois, Pierre Corbeau, Charline Duquenne
  • Design of novel highly efficient HIV based packaging systems for gene therapy
    Patent number: 6323019
    Abstract: By transducing cells with an HIV-1-MN molecular clone deleted in the major packaging sequence, a stable HIV-1 packaging cell line, &psgr;422 was produced. &psgr;422 cells form syncytia with CD4 positive cells, correctly express HIV-1 structural proteins, and produce large amount of mature particles with normal RT activity. These particles are not infectious. When stably transfected with an HIV-based retroviral vector, the &psgr;422 cell line produces hybrid virions capable of transducing CD4 positive cells with high efficiency (e.g., 105 cells/ml). The availability of this stable, noninfectious HIV-1 packaging cell line capable of generating high titer HIV vectors enables the use of HIV-1 based nucleic acids delivery systems, for example, in gene therapy. An HIV-2 based vector is packaged by the packaging cell lines, demonstrating that HIV-2 cell transformation vectors are packaged by the packaging cell line.
    Type: Grant
    Filed: August 10, 1998
    Date of Patent: November 27, 2001
    Assignee: The Regents of the University of California
    Inventors: Pierre Corbeau, Gunter Kraus, Flossie Wong-Staal
  • Cell transformation vector comprising an HIV-2 packaging site nucleic acid and an HIV-1 GAG protein
    Patent number: 6200811
    Abstract: By transducing cells with an HIV-1-MN molecular clone deleted in the major packaging sequence, a stable HIV-1 packaging cell line, &psgr;422 was produced. &psgr;422 cells form syncytia with CD4 positive cells, correctly express HIV-1 structural proteins, and produce large amount of mature particles with normal RT activity. These particles are not infectious. When stably transfected with an HIV-based retroviral vector, the &psgr;422 cell line produces hybrid virions capable of transducing CD4 positive cells with high efficiency (e.g., 105 cells/ml). The availability of this stable, noninfectious HIV-1 packaging cell line capable of generating high titer HIV vectors enables the use of HIV-1 based nucleic acids delivery systems, for example, in gene therapy. An HIV-2 based vector is packaged by the packaging cell lines, demonstrating that HIV-2 cell transformation vectors are packaged by the packaging cell line.
    Type: Grant
    Filed: March 24, 1997
    Date of Patent: March 13, 2001
    Assignee: The Regents of the University of California
    Inventors: Pierre Corbeau, Gunter Kraus, Flossie Wong-Staal